• PHF2 and Neuroinflammation in Alzheimer’s Disease

  2026-10-12

  A 2025 Molecular Psychiatry study identifies the histone demethylase PHF2 as a regulator of inflammatory gene expression in Alzheimer’s disease models. Its findings connect increased PHF2 expression with glial activation, impaired glutamatergic synaptic function and memory deficits, while PHF2 knockdown improved several disease-associated measures in a familial Alzheimer’s mouse model; however, the evidence remains preclinical and does not establish a human therapeutic effect.

• PEP, cGAS–STING and Healthy Aging

  2026-10-12

  A 2026 Nature Aging study reports that phosphoenolpyruvate, or PEP, may act as an endogenous brake on cGAS–STING-driven inflammation during aging. The findings concern PEP specifically—not hexose diphosphate—and support a mechanistic link between glycolytic metabolism and inflammaging while remaining limited by the study’s preclinical design and observational human associations.

• T-5224: From AP-1 Biology to Ferroptosis

  2026-10-10

  T-5224 is a C-Fos/AP-1 inhibitor with established relevance to inflammatory signaling and emerging evidence in multiple myeloma. This article interprets how AP-1 suppression may connect PI3K/AKT signaling with ferroptosis while defining the limits of translation from arthritis research to oncology.

• T-5224: C-Fos/AP-1 Inhibitor Evidence

  2026-10-09

  T-5224 is a C-Fos/AP-1 inhibitor with reported selectivity for c-Fos/c-Jun DNA binding. Evidence spans inflammatory cell models, collagen-induced arthritis (CIA) models, and a 2024 multiple myeloma study that linked AP-1 inhibition with ferroptosis through PI3K/AKT signaling.

• EZ Cap EGFP mRNA: Evidence and Research Context

  2026-10-09

  EZ Cap EGFP mRNA is a Cap 1 reporter-mRNA tool for studying delivery and transient protein expression. This overview places the product concept alongside Duoto et al.’s 2025 study of potato virus X nucleoprotein platforms, separating published findings from interpretation and outlining evidence limits.

• Perphenazine: Research Context and Evidence

  2026-10-08

  Perphenazine is a dopamine D2 receptor antagonist with established neuropharmacology relevance and emerging interest in host-directed antibacterial research. This overview compares the evidence for macrophage immune activation, mitochondria-mediated cell death induction, and opioid tolerance suppression while defining the limitations that separate cell and animal findings from clinical conclusions.

• Mianserin HCl: Evidence, Uses, and Limits

  2026-10-08

  A source-grounded overview of Mianserin HCl covering its historical antidepressant evidence, 5-HT2 receptor research context, proposed antipathogenic applications, and the limitations of current evidence.

• Q-VD-OPh in Apoptosis Research: Evidence and Limits

  2026-10-07

  Q-VD-OPh is widely described as a cell-permeable pan-caspase inhibitor for probing caspase-dependent cell death. This overview separates supplier-reported properties from peer-reviewed evidence, explains its conceptual value in apoptosis research, and examines the limits of claims involving cryopreservation, neurodegeneration, and Alzheimer’s disease research. The supplied breast cancer study provides useful context for apoptosis and senescence biology but does not directly validate Q-VD-OPh.

• Temafloxacin Activity Against Gram-Positive Bacteria

  2026-10-07

  The 1991 reference study combined new susceptibility data from blood-culture isolates with a literature review to examine temafloxacin against clinically important Gram-positive cocci. Its findings support stronger in-vitro activity than ciprofloxacin or ofloxacin against several staphylococcal and pneumococcal groups, while also showing why laboratory context limits direct clinical interpretation.

• Carrier-Platin and Rapid ROS-Driven Cancer Cell Death

  2026-10-06

  Liu and colleagues describe carrier-platin, a platinum-based nanotherapeutic designed to generate a rapid intracellular reactive oxygen species burst rather than relying on conventional DNA damage. The reported preclinical evidence supports a distinct, non-apoptotic and non-ferroptotic death phenotype, including activity in multidrug-resistant cancer models, while leaving important questions about mechanism, selectivity, and clinical translation unresolved.

• Bifidobacterium, FMT, and Neuroinflammation in HE

  2026-10-06

  A 2025 European Journal of Neuroscience study used [18F]PBR146 micro-PET/CT to compare Bifidobacterium and fecal microbiota transplantation in rats with chronic hepatic encephalopathy. Although global brain tracer uptake, behavior, and measured cytokines did not differ significantly, regional imaging and microbiome profiles suggested that Bifidobacterium may attenuate neuroinflammatory responses more consistently than FMT in this model.

• MRSA EVs Drive IL-8-Dependent OSCC Growth

  2026-10-05

  A 2026 study reports that extracellular vesicles from methicillin-resistant Staphylococcus aureus promote oral squamous cell carcinoma growth more strongly than vesicles from methicillin-susceptible S. aureus. The work links bacterial vesicle uptake to ERK/c-Jun signaling, IL-8 production, CXCR1 activity, and downstream tumor proliferation, while genetic and pharmacological pathway interventions provide in vivo support.

• Minocycline HCl and the Retinal Microglia Frontier

  2026-10-05

  A source-grounded analysis of how minocycline HCl helps interrogate microglial activity, MHC-II signaling, and amyloid-β clearance in retinal aging research—while defining the limits of translating mouse findings into therapeutic strategy.

• PGF2α/PTGFR Drives Endometrial Breakdown

  2026-10-04

  A 2024 mouse menstrual-like model study identifies PGF2α/PTGFR signaling as an important regulator of endometrial disintegration and vascular permeability after progesterone withdrawal. The work further connects HIF-1α-dependent transcriptional control of Ptgfr with angiogenic balance, while pharmacological inhibition provides evidence for a causal contribution to tissue breakdown.

• Fluoxetine HCl in Serotonin and Motivation Research

  2026-10-03

  A source-grounded overview of Fluoxetine HCl research, focusing on serotonergic signaling, developmental SSRI exposure, reward-related behavior, and the evidence linking nucleus accumbens mu opioid receptors to motivation deficits in mice. The discussion distinguishes supplier information from dissertation findings and outlines translational limits without providing experimental procedures.

8567 records 1/572 page Next 12345 下5页 Last page